We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Choosing & Using Fragments in the Generation of Selective Kinase Inhibitors
Video

Choosing & Using Fragments in the Generation of Selective Kinase Inhibitors

Choosing & Using Fragments in the Generation of Selective Kinase Inhibitors
Video

Choosing & Using Fragments in the Generation of Selective Kinase Inhibitors

Finding fragments that bind to such targets is straight-forward. For most kinases, a screen of our 1350 member fragment library results in between 40 to 170 validated and chemically distinct hits. In addition, crystal structures for these hits bound to the kinase can usually be obtained quite rapidly. The real challenge is how to digest all this information and decide how and which fragments to progress in order to identify the highest quality leads. My presentation will illustrate the approach taken at Vernalis in some recent projects which led to the discovery of novel lead series for a number of different kinases. The main messages are that: fragments always tell you something new about the binding site; careful triage and exploration of fragment SAR can give indications of how to achieve selectivity, novelty and affinity;it is important to optimise the fragment before investing large chemistry resources and that with patience, a fragment derived series will often supersede an HTS derived series and deliver a better quality of compound for lead optimisation.
Advertisement